Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib

Loading...
Loading...
Pfizer Inc. announced today that the U.S. Food and Drug Administration has accepted its New Drug Application for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive chronic myeloid leukemia. This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in over 500 patients with previously treated Ph+ CML, including patients resistant or intolerant to imatinib as well as patients who were previously treated with dasatinib or nilotinib. Currently, there are no approved therapies available for CML patients after second-line treatment with dasatinib or nilotinib.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...